Natural Product-Drug Interaction Research: The Roadmap to Best Practices

天然产物-药物相互作用研究：最佳实践路线图

• 批准号: 8977997
• 负责人: MARY F PAINE
• 金额: $ 201.52万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-09-01 至 2020-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8977997
• 关键词: Address; Archives; Biological Factors; Clinical; Collaborations; Communication; Communities; Complement; Computer Simulation; Data; Databases; Decision Trees; Drug Interactions; Drug Kinetics; Ensure; Future; Goals; Health; Healthcare; Human; In Vitro; Individual; Informatics; Infrastructure Activities; Investigation; Knowledge; Leadership; Literature; Methods; Names; National Center for Complementary and Alternative Medicine; Natural Product Drug; Natural Products Chemistry; Nature; Online Systems; Pharmaceutical Preparations; Pharmacology; Procedures; Process; Qualifying; Quality Control; Research; Research Personnel; Risk; Safety; Sales; Sampling; Series; Source; Vulnerable Populations; Work; base; clinically relevant; data mining; design; experience; improved; in vivo; innovation; liquid chromatography mass spectrometry; models and simulation; multidisciplinary; novel; operation; perpetrators; pharmacokinetic model; public health relevance; quality assurance; repository

 DESCRIPTION (provided by applicant): As natural products (NP) sales increase, the risk of adverse NP-drug interactions (NPDIs) increases, yet the pharmacokinetic (PK) elucidation and clinical relevance of putative NPDIs remain elusive. Assessing the risk of NPDIs is more challenging than that of drug-drug interactions (DDIs), often due to relatively scant PK knowledge of individual NP constituents that perpetrate these interactions. The proposed U54 Center will develop a roadmap for NPDI research through a series of well-designed human in vitro and in vivo studies (termed Interaction Projects) on 4-6 priority NPs that pose a potential risk for clinically relevant NPDIs. A repository will be developed for the data generated from the Interaction Projects, and results will be communicated to various target audiences through a public portal. This U54 Center is composed of an accomplished team of investigators, including pharmacokineticists with expertise in NPDIs, complemented by expertise in NP chemistry, DDIs, and health information communication. In collaboration with the Steering Committee, an innovative strategy that combines a mechanistic approach with practical considerations (e.g., popularity of the NPs) will be used to select and prioritize 4-6 NPs for further investigation in te Interaction Projects. Mechanistic aspects include curated clinical NDPI data from the widely used Drug Interaction Database (DIDB) of the Informatics Core, structural alerts, and compelling preliminary clinical and in silico NPDI data. Once selected, the NPs will be entered into a Decision Tree for assessment of NPDI liability and probable significance of interactions with victim drugs. In parallel, the Pharmacology Core will develop detailed Statements of Work for the human in vitro and in vivo studies - while the Analytical Core will source, acquire, and characterize the selected NPs - for the Interaction Projects. Upon completion of each project, the Analytical Core will analyze the PK samples, and the Pharmacology Core will develop physiologically-based PK models for further assessment of the clinical relevance of the Interaction Project results. Throughout these projects, the Informatics Core will create a data repository embedded within a public portal web-based application named, NaPDI app, for Natural Product-Drug Interaction application. The repository, built using the DIDB framework, will allow researchers to access both raw data and summarized results. The U54 Center will also develop and share Best Practices recommended for the conduct of NPDI studies, based on the experience with and results from the Interaction Projects, with the research communities via the public portal. Effective dissemination of the Interaction Project results will be ensured through user experience and brand content studies with target audiences - researchers/practitioners and lay public - to refine the public portal content. The Informatics Core will ensure that the U54 Center's results are archived, organized, analyzed, and well-publicized, allowing for improved design of future NPDI research and ultimately, improved decisions on the optimal management of clinically relevant NPDIs.

 描述(由申请人提供)：随着天然产物(NP)销售的增加，NP-药物不良相互作用(NPDI)的风险增加，但推定的NPDI的药代动力学(PK)阐明和临床相关性仍然难以捉摸。评估NPDI的风险比评估药物-药物相互作用(DDIS)的风险更具挑战性，这通常是因为对进行这些相互作用的单个NP成分的PK知识相对较少。拟建的U54中心将通过对4-6个对临床相关的NPDI构成潜在风险的优先NPs进行一系列精心设计的人体体外和体内研究(称为交互项目)，为NPDI研究制定路线图。将为互动项目产生的数据开发一个储存库，并通过公共门户将结果传达给不同的目标受众。U54中心由一支经验丰富的研究团队组成，其中包括具有NPDIs专业知识的药代动力学专家，以及NP化学、DDIS和健康信息交流方面的专业知识。在指导委员会的协作下，将采用一种创新战略，将机械性方法与实际考虑因素(例如，国家警察的受欢迎程度)相结合，以选择4-6个国家警察并确定优先次序，以便在TE互动项目中进行进一步调查。机制方面包括从信息学核心的广泛使用的药物相互作用数据库(DIDB)中精选的临床NDPI数据、结构警报以及令人信服的初步临床和电子NPDI数据。一旦被选中，这些NP将被输入决策树，以评估NPDI的责任和与受害者药物相互作用的可能意义。同时，药理学核心将为人体体外和体内研究制定详细的工作说明，而分析核心将为相互作用项目寻找、获取和表征选定的NP。在每个项目完成后，分析核心将分析PK样本，而药理学核心将开发基于生理的PK模型，以进一步评估互动项目结果的临床相关性。在所有这些项目中，信息学核心将创建一个嵌入公共门户网站应用程序中的数据存储库，该应用程序名为NaPDI app，用于天然产品-药物交互应用程序。使用DIDB框架建立的存储库将允许研究人员访问原始数据和汇总结果。U54中心还将根据互动项目的经验和结果，通过公共门户与研究界制定和分享为开展NPDI研究建议的最佳做法。互动项目成果的有效传播将通过与目标受众--研究人员/从业者和公众--进行的用户体验和品牌内容研究来确保，以完善公共门户内容。信息学核心将确保U54中心的结果得到存档、组织、分析和广泛宣传，从而改进未来NPDI研究的设计，并最终改进临床相关NPDI最佳管理的决策。